Allergan to Develop Editas CRISPR Therapy EDIT-101 for LCA10

Allergan plans to develop and commercialize Editas Medicine’s CRISPR genome editing treatment candidate EDIT-101 globally for Leber Congenital Amaurosis type 10 (LCA10), a development effort that could generate up to $40 million for Editas.Editas has already received $15 million after a wholly-owned Allergan subsidiary, Allergan Pharmaceuticals, exercised its option to develop and commercialize EDIT-101—an option held under a strategic alliance and option agreement between the compan